Switching from VEDOlizumab intravenous to subcutaneous formulation in ulcerative colitis patients in clinical remission: The SVEDO Study, an IG-IBD study

The administration of biological drugs in inflammatory bowel diseases (IBD) is increasingly moving from intravenous to subcutaneous formulations.

Source: Digestive and Liver Disease - July 19, 2023 Category: Gastroenterology Authors: Davide Giuseppe Ribaldone, Laura Parisio, Angela Variola, Fabrizio Bossa, Fabiana Castiglione, Manuela Marzo, Nicole Piazza, Annalisa Aratari, Edoardo Vincenzo Savarino, Giorgia Bodini, Mauro Mastronardi, Federica Micheli, Silvia Mazzuoli, Marta Ascolani, Tags: Alimentary Tract Source Type: research